SG3 Management’s Celularity CELU Stock Holding History

SG3 Management’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,282	Closed	-$936K	–	1068
2021 Q1	$936K	Buy	+9,282	New	+$951K	0.02%	620

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SG3 Management's CELU Position: Q2 2021 in Review

SG3 Management sold out of Celularity (CELU) in Q2 2021, closing a stake of 9,282 shares — an estimated $936K sold.

SG3 Management first reported a position in CELU in Q1 2021 and held it in 1 quarter. The position peaked at $936K in Q1 2021. 33 funds tracked by Wall St. Rank hold CELU as of Q2 2021.

SG3 Management reported no remaining Celularity position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 9,282 Celularity shares in Q2 2021, an estimated $936K.
SG3 Management first reported a position in Celularity in Q1 2021 and held it in 1 quarter.
SG3 Management's Celularity position peaked at $936K in Q1 2021.
33 funds tracked by Wall St. Rank held Celularity as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.